ClinicalTrials.gg
Not yet recruitingNCT07900568Updated Oct 28, 2026

Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma

A Phase 1 interventional study of HXN-1013 and Placebo in Health Adults and Asthma, sponsored by Helixon Biotechnology (Suzhou) Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Helixon Biotechnology (Suzhou) Co., Ltd · Phase 1, Interventional, and Treatment

Updated Oct 28, 2026Newly registeredGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.

Read the detailed description

This study consists of four sequential single ascending dose (SAD) cohorts in healthy participants (Cohorts 1-4) and one separate cohort in participants with mild-to-moderate asthma (Cohort 5).

Approximately eight participants will be enrolled per cohort, with an overall allocation ratio of HXN-1013 to placebo of 6:2. A Safety Review Committee (SRC) will review accumulated safety, PK, and PD data before dose escalation to the next cohort. Cohort 5 (participants with asthma) will be conducted at a dose already evaluated in healthy participants.

HXN-1013 or placebo will be administered as a single subcutaneous injection on Day 1. Participants will be followed for safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity up to Day 141 (±7 days). HXN-1013 is a recombinant humanized bispecific antibody simultaneously targeting thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33).

02

Conditions studied

  • Health Adults
  • Asthma

Browse trials for

03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's planned enrollment of 40 is below the median of 78 across 3,341 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Helixon Biotechnology (Suzhou) Co., Ltd is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be able to understand and comply with the study requirements and voluntarily sign the form (ICF).
  2. (Healthy participants) Male or female aged 18 to 55 years (inclusive) at signing of the ICF.
  3. (Healthy participants) Male participants weighing ≥ 50.0 kg or and female participants ≥ 45.0 kg, with a (BMI) between 18.0-32.0 kg/m² (inclusive).
  4. (Participants with asthma) Participants must have documented physician-diagnosed asthma for ≥12 months, pre-bronchodilator ≥60% predicted, objective evidence of variable airflow limitation, and well-controlled disease (GINA) on permitted stable background therapy.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women; women planning pregnancy within 180 days after dosing.
  2. Active or suspected infection within 30 days prior to randomization; positive IGRA indicative of active tuberculosis; positive , syphilis, , or antibody.
  3. History of within 5 years (except resected basal/squamous cell carcinoma of the skin).
  4. History of reactions (e.g., anaphylaxis, angioedema) to biologic agents or to study drug .
  5. Use of therapeutic antibodies within 5 half-lives prior to dosing; experimental agent within 30 days or 5 half-lives; within 30 days or non-live vaccines within 14 days.
  6. Clinically significant abnormalities (e.g., ≥450 ms male / ≥470 ms female).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HXN-1013 (Healthy Participant)

    Healthy participants.

    Drug: HXN-1013

  • Placebo comparator
    Placebo (Healthy Participant)

    Healthy participants.

    Drug: Placebo

  • Experimental
    HXN-1013 (Asthma)

    Participants with asthma.

    Drug: HXN-1013

  • Placebo comparator
    Placebo (Asthma)

    Participants with asthma.

    Drug: Placebo

Interventions

  • DrugHXN-1013

    Participants will receive a single subcutaneous dose of HXN-1013.

  • DrugPlacebo

    Participants will receive a single subcutaneous dose of placebo.

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence, severity, and causal relationship of Adverse Events (AEs)

    Time frame: Up to day 141

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    The maximum (peak) observed drug concentration in plasma after administration.

    Time frame: Up to day 141

  2. Area Under the Plasma Concentration Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t)

    Area under the plasma concentration-time curve from time 0 (pre-dose) to the time of the last measurable (quantifiable) plasma concentration.

    Time frame: Up to day 141

  3. Time to Maximum Concentration (Tmax)

    Time to reach peak serum concentration

    Time frame: Up to day 141

  4. Incidence of anti-drug antibodies (ADA) against HXN-1013

    Incidence of treatment-emergent ADA in serum samples

    Time frame: Up to day 141

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07900568
Responsible party
Sponsor
First posted
Oct 28, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 15, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Tong Gang
Contact
tonggang@helixon.com
+86 13918569690

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion